Bruker agreed to pay AbCellera $36 million and royalties to resolve patent litigation tied to microfluidic single‑cell platforms. The settlement covers Bruker’s Beacon‑derived Optofluidic platform products and includes a license to AbCellera’s patents through their life. The deal defuses a multi‑year legal dispute that had its origins in litigation over single‑cell antibody discovery and streamlines commercialization risks for both vendors and downstream customers using these platforms.